AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IMDX · NASDAQ · Medical - Diagnostics & Research

Insight Molecular Diagnostics

Develops molecular diagnostic tests for transplant rejection and oncology therapy programs.

$4.13

After-hours close0.00 (0.00%)

At close$4.13(−3.73%)

Something off on this page? Send us feedback.

Profile

Insight Molecular Diagnostics Inc.IMDXHealth Care

Focuses molecular diagnostic work on testing for transplanted-organ rejection while retaining intellectual-property programs for oncology therapy selection and therapy monitoring. Its portfolio spans laboratory-developed tests, research-use-only kits, and in-vitro-diagnostic kitted clinical tests.

Centers its operating focus on molecular testing for transplanted-organ rejection after a pivot from the wider OncoCyte portfolio. A name change and move to Nashville accompanied that refocus. The rebranded company retains intellectual-property programs for oncology therapy selection and therapy monitoring alongside its organ-transplant work.

Uses laboratory-developed tests, research-use-only kits, and in-vitro-diagnostic kitted clinical tests. Its principal executive office and CLIA-certified laboratory are in Nashville; it stated that it expects to retain a laboratory and R&D center in Göttingen, Germany. The portfolio is organized around organ transplant, oncology therapy selection, and oncology therapy monitoring.

Company facts

CEOJoshua Riggs

ListedJan 4, 2016

ExchangeNASDAQ

HeadquartersNashville, TN

CountryUnited States

Employees58

CIK0001642380

ISINUS68235C2061

Key statistics

Market cap$133.4M

EPS (ttm)−$1.52

P/E (ttm)−2.72

ROE271.8%

P/B−7.13

P/S79.86

Dividend yield—

Beta2.51vs XLV 0.27

Year to date −42.3% · Average volume (30d) 173.9K

Analysts

Price target, next 12 months$9.50+130.0%Median of 11 analysts · vs the Aug 28 close

ConsensusBuy7 of 11 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $4.13

High$12.00+190.6%

Median$9.50+130.0%

Low$8.00+93.7%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Feb 17, 2026	Lake Street	Reiterate	Buy	$0.50	$12
Nov 11, 2025	Needham	Reiterate	Buy	$4.25	$9

Earnings

EPS

Estimate−$0.23

ReportedDue Nov 9, 2026

Revenue

Estimate$215.1K

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	−$0.25	−$0.31	−22.1%	$352.5K	$239.0K	−32.2%	−7.13%
May 13, 2026Q1 FY26	−$0.26	−$0.28	−7.1%	$229.2K	$32.0K	−86.0%	+25.88%
Mar 26, 2026Q4 FY25	−$0.24	−$0.27	−13.7%	$285.0K	$1.1M	+299.6%	−13.38%
Nov 10, 2025Q3 FY25	−$0.24	−$0.34	−41.7%	$285.0K	$260.0K	−8.8%	+10.74%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$2.1M	$518.0K	$260.0K	$1.1M	$32.0K	$239.0K
Gross profit	$1.3M	$350.0K	$139.0K	$496.0K	−$605.5K	$157.0K
Operating income	−$6.8M	−$9.8M	−$11.0M	−$10.0M	−$10.3M	−$11.4M
Net income	−$6.7M	−$9.7M	−$10.9M	−$23.0M	−$4.3M	−$11.3M
Diluted EPS	−$0.26	−$0.30	−$0.34	−$0.75	−$0.12	−$0.31
Gross margin	62.0%	67.6%	53.5%	43.5%	-1,892.2%	65.7%
Operating margin	-318.0%	-1,900.0%	-4,249.2%	-873.6%	-32,284.4%	-4,770.7%

Fiscal years (4-quarter sums)FY21 $7.7M · FY22 $958.0K · FY23 $1.5M · FY24 $1.9M · FY25 $4.1M

Revenue by product · Q1 FY26

Laboratory Services$32.0K · 100%

Revenue by geography · Q1 FY26

United States$32.0K · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $17.8M · Total debt $2.6M · Total assets $29.4M · Shareholders' equity −$21.3M

Dividends

No dividends on record.

Ownership

Institutions 58.65%18.94M sharesInsiders 1.61%519.5K sharesOther 39.74%12.83M shares

Shares outstanding 32.29M · Float 10.08M · 31.2% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Broadwood Partners, L.P. · 10 percent owner	25.37M	78.57%	Form 4	Apr 27, 2026
Neal C. Bradsher	12.84M	39.70%	13D	Apr 27, 2026
Broadwood Capital Inc	11.93M	36.95%	13F	May 15, 2026
Awm Investment Company, Inc.	2.81M	8.69%	13F	May 15, 2026
Bio-Rad Laboratories, Inc	2.76M	9.70%	13G	Mar 4, 2025

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Apr 23, 2026	Broadwood Partners, L.P.	10 percent owner	+280,381	$3.50
Apr 24, 2026	Broadwood Partners, L.P.	10 percent owner	+38,880	$3.53
Apr 27, 2026	Broadwood Partners, L.P.	10 percent owner	+250,923	$3.64
Apr 16, 2026	Broadwood Partners, L.P.	10 percent owner	+102,057	$3.45
Apr 17, 2026	Broadwood Partners, L.P.	10 percent owner	+40,114	$3.57